Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 6
Submit an article Journal homepage
253
Views
13
CrossRef citations to date
0
Altmetric
Original Articles

Phase I study of AR-42 and decitabine in acute myeloid leukemia

Sophia G. LivaDivision of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA; View further author information
,
Christopher C. CossDivision of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA; View further author information
,
Jiang WangCenter for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA; View further author information
,
William BlumDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA; View further author information
,
Rebecca KlisovicDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA; View further author information
,
Bhavana BhatnagarDivision of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; View further author information
,
Katherine WalshDivision of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; View further author information
,
Susan GeyerMayo Clinic, Rochester, MN, USA; View further author information
,
Qiuhong ZhaoDivision of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; View further author information
,
Ramiro GarzonDivision of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; View further author information
,
Guido MarcucciDepartment of Hematologic Malignancies Translational Science, City of Hope, Duarte, CA, USAView further author information
,
Mitch A. PhelpsDivision of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA; View further author information
&
Alison R. WalkerDivision of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA; Correspondence[email protected]
View further author information
 show all
Pages 1484-1492 | Received 04 Nov 2019, Accepted 16 Jan 2020, Published online: 08 Feb 2020

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

R. Kundu, S. Banerjee, S.K. Baidya, N. Adhikari & T. Jha. (2022) A quantitative structural analysis of AR-42 derivatives as HDAC1 inhibitors for the identification of promising structural contributors. SAR and QSAR in Environmental Research 33:11, pages 861-883.
Read now

Articles from other publishers (12)

Yun Deng, Qian Cheng & Jing He. (2023) HDAC inhibitors: Promising agents for leukemia treatment. Biochemical and Biophysical Research Communications 680, pages 61-72.
Crossref
LaShanale Wallace & Esther A. Obeng. (2023) Noncoding rules of survival: epigenetic regulation of normal and malignant hematopoiesis. Frontiers in Molecular Biosciences 10.
Crossref
Casey J. Lumpkin, Ashlee W. Harris, Andrew J. Connell, Ryan W. Kirk, Joshua A. Whiting, Luciano Saieva, Livio Pellizzoni, Arthur H. M. Burghes & Matthew E. R. Butchbach. (2023) Evaluation of the orally bioavailable 4-phenylbutyrate-tethered trichostatin A analogue AR42 in models of spinal muscular atrophy. Scientific Reports 13:1.
Crossref
Ailin Zhao, Hui Zhou, Jinrong Yang, Meng Li & Ting Niu. (2023) Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. Signal Transduction and Targeted Therapy 8:1.
Crossref
Amit Kumar, Luni Emdad, Paul B. Fisher & Swadesh K. Das. 2023. Epigenetic Regulation of Cancer in Response to Chemotherapy. Epigenetic Regulation of Cancer in Response to Chemotherapy 73 161 .
Gui‐Hong Liu, Tao Chen, Xin Zhang, Xue‐Lei Ma & Hua‐Shan Shi. (2022) Small molecule inhibitors targeting the cancers. MedComm 3:4.
Crossref
Sophia Liva, Min Chen, Amir Mortazavi, Alison Walker, Jiang Wang, Kristin Dittmar, Craig Hofmeister, Christopher C. Coss & Mitch A. Phelps. (2021) Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing. European Journal of Drug Metabolism and Pharmacokinetics 46:6, pages 807-816.
Crossref
Bhavana Bhatnagar & Ramiro Garzon. (2021) Clinical Applications of MicroRNAs in Acute Myeloid Leukemia: A Mini-Review. Frontiers in Oncology 11.
Crossref
Katharine A. Collier, Hugo Valencia, Herbert Newton, Erinn M. Hade, Douglas W. Sborov, Robert Cavaliere, Ming Poi, Mitch A. Phelps, Sophia G. Liva, Christopher C. Coss, Jiang Wang, Soun Khountham, Paul Monk, Charles L. Shapiro, Richard Piekarz, Craig C. Hofmeister, D. Bradley Welling & Amir Mortazavi. (2021) A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. Cancer Chemotherapy and Pharmacology 87:5, pages 599-611.
Crossref
Pu Zhang, Lindsey T. Brinton, Katie Williams, Steven Sher, Shelley Orwick, Lai Tzung-Huei, Alice S. Mims, Christopher C. Coss, Samuel K. Kulp, Youssef Youssef, Wing Keung Chan, Shaneice Mitchell, Allison Mustonen, Matthew Cannon, Hannah Phillips, Amy M. Lehman, Tierney Kauffman, Larry Beaver, Daniel Canfield, Nicole R. Grieselhuber, Lapo Alinari, Deepa Sampath, Pearlly Yan, John C. Byrd, James S. Blachly & Rosa Lapalombella. (2021) Targeting DNA Damage Repair Functions of Two Histone Deacetylases, HDAC8 and SIRT6, Sensitizes Acute Myeloid Leukemia to NAMPT Inhibition. Clinical Cancer Research 27:8, pages 2352-2366.
Crossref
Kunal Nepali & Jing-Ping Liou. (2021) Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. Journal of Biomedical Science 28:1.
Crossref
Donglu Wu, Ye Qiu, Yunshuang Jiao, Zhidong Qiu & Da Liu. (2020) Small Molecules Targeting HATs, HDACs, and BRDs in Cancer Therapy. Frontiers in Oncology 10.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.